About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
https://www.weizmann-usa.org/news-media/in-the-news/the-transformation/
Sep 15, 2014...
An experimental new drug can make some leukemic cells mature into healthier ones. Illustration by Brian Stauffer
For almost thirty years, William Kuhens worked on Staten Island as a basketball referee for the Catholic Youth Organization and other amateur leagues. At seventy, he was physically fit, taking part in twenty games a month. But in July of 2013 he began to lose weight and feel exhausted; his wife told him he looked pale. He saw his doctor, and tests revealed that his blood contained below-normal numbers of platelets and red and white blood cells; these are critical for, respectively, preventing bleeding, supplying oxygen, and combatting infection. Kuhens was sent to the Memorial Sloan Kettering Cancer Center, in Manhattan, to meet with Eytan Stein, an expert in blood disorders. Stein found that as much as fifteen per cent of Kuhens’s bone marrow was made up of primitive, cancerous blood cells. “Mr. Kuhens was on the cusp of leukemia,” Stein told me recently. “It seemed that his disease was rapidly advancing.”
May 03, 2012...
Do you know that skin cancer is the most common form of cancer? And that it’s on the rise, with increased incidence over the last 30 years? In fact, the American Cancer Society estimates that, in 2013, almost 77,000 new melanomas will be diagnosed in the U.S. alone, and over 9,000 people will die of the disease.
While prevention and early screening are critical, fighting skin cancer once it develops is still a challenge. That’s why researchers at the Weizmann Institute of Science are attacking skin cancer and melanoma from a number of angles, including:
Mar 24, 2019...
Trial-In CEO Nir Erez. (photo credit: Courtesy)
Working in the field of oncology was a case of love at first sight for Weizmann Institute of Science graduate Nir Erez.
In 2003, after completing his Master’s degree, Erez joined pharma giant Roche Pharmaceuticals (Israel), which specializes in the development and marketing of cancer drugs. There, he worked alongside leading oncologists, learned of breakthrough cancer treatments and the development and types of the disease.
Oct 29, 2014... Prof. Michal Neeman spoke at the 2014 Global Gathering session, Partners in Scientific Advancement, about why it's so important for us to get high-resolution images of cancer. Today's instrumentation allows scientists to actually observe cancer in the body, providing invaluable new data. Of course, staying on top of the technology, much less knowing how to maximize its use, is also a challenge.
https://www.weizmann-usa.org/news-media/in-the-news/ema-approves-steba-s-prostate-cancer-drug/
Sep 25, 2017...
Raphael and Fabrice Harari
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended by a majority of 29-2 the approval for marketing of the Tookad drug for treatment of prostate cancer developed by Israeli company Steba Biotech. Tookad is a complex treatment, in which the patient takes a drug, but the drug is activated only in the area of the tumor, through the skin. The product, developed by Professor Avigdor Scherz and Dr. Yoram Salomon of the Weizmann Institute of Science, has already been approved for marketing and sale in Israel and Mexico.
Sep 02, 2007...
BROADCAST TRANSCRIPT
Date: September 02, 2007
Time: 01:00 PM - 02:00 PM
Station: Fox News Channel
Location: Network
Program: Weekend Live
STEVE CENTANNI, co-anchor: How many times have you been told that cell phones are not bad for your health? Probably a lot. But hold on a second, there's a new study out this week that challenges that notion. Researchers at the Weizmann Institute of Science in Israel have found evidence cell phone radiation does react with your brain cells and that could lead to cancer.
Sep 17, 2018... September is both Prostate Cancer Awareness Month and Ovarian Cancer Awareness Month in the U.S., where prostate cancer is the most common cancer (after skin cancer) in men: about 1 in 7 will be diagnosed during his lifetime. However, as the American Cancer Society points out, prostate cancer is now quite treatable, and “most men diagnosed with prostate cancer do not die from it.” But there is still progress to be made: for example, current treatments can have undesirable side effects, such as erectile dysfunction and urinary incontinence.
Jul 13, 2013...
Kertesz. 'Israel has an abundance of talent and motivation, but not of biotech investments. [Biotech] requires tens of millions of dollars and years of development, which aren’t always fruitful.' Photo by Eyal Toueg
A small American start-up managed to streamline complex DNA-sequencing techniques. Its co-founder, Mickey Kertesz, thinks the greatest breakthrough may come in the field of cancer treatment.
https://www.weizmann-usa.org/news-media/in-the-news/camera-sees-through-skin-around-corners/
Oct 21, 2012...
Weizmann Institute researchers Ori Katz, left, and Eran Small.
Researchers at the Weizmann Institute of Science in Rehovot, Israel, have discovered a new physics trick. While it's not exactly Superman vision — yet — the camera developed by Ori Katz, Eran Small and Prof. Yaron Silberberg sees through objects using a simple light bulb, a standard digital camera and the basic technology found in everyday digital projectors.
https://www.weizmann-usa.org/news-media/news-releases/predicting-immunotherapy-success/
Feb 18, 2020... REHOVOT, ISRAEL—February 18, 2020—One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy. Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. Their findings were reported in Nature Communications.
©2022 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR